Cellyan Biotechnology Co., Ltd
HKPD· Nasdaq
Who holds Cellyan Biotechnology Co., Ltd, from the managers’ Form 13F reports for the quarter ended Sep 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| StoneX Group Inc. | 132.3K | +29.3% | $33.9K | 0.1% | Nov 3, 2026 |
| XTX Topco Ltd | 131.8K | +238.5% | $15.3K | 0.1% | Nov 16, 2026 |
| Jane Street Group, LLC | 81.8K | +66.6% | $9.5K | 0% | Nov 12, 2026 |
| Citadel Advisors LLC | 33K | New | $3.8K | 0% | Nov 16, 2026 |
| Two Sigma Securities, LLC | 15.1K | New | $1.7K | 0.1% | Nov 16, 2026 |
| Clear Street Group Inc. | 12K | ±0% | $1.4K | 0% | Nov 16, 2026 |
| JPMorgan Chase & Co | 112 | New | $12 | 0% | Nov 12, 2026 |
| HRT Financial LP | 100.7K | +140.7% | $11 | 0% | Nov 13, 2026 |
| Virtu Financial LLC | 18.9K | New | $2 | 0.1% | Nov 17, 2026 |